Algert Global LLC Purchases 47,008 Shares of LivaNova PLC (NASDAQ:LIVN)

Algert Global LLC increased its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 81.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 105,017 shares of the company's stock after buying an additional 47,008 shares during the period. Algert Global LLC owned 0.19% of LivaNova worth $5,518,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fifth Third Bancorp increased its holdings in shares of LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company's stock worth $37,000 after purchasing an additional 332 shares during the period. Hexagon Capital Partners LLC increased its stake in LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock valued at $37,000 after acquiring an additional 370 shares during the period. Lazard Asset Management LLC acquired a new position in LivaNova in the 1st quarter valued at approximately $84,000. Canada Pension Plan Investment Board bought a new stake in shares of LivaNova in the 2nd quarter worth approximately $88,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of LivaNova during the 1st quarter worth approximately $94,000. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Price Performance

LIVN stock traded up $0.43 during trading on Monday, hitting $51.75. 415,980 shares of the stock traded hands, compared to its average volume of 613,655. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market cap of $2.81 billion, a price-to-earnings ratio of 123.64 and a beta of 1.01. LivaNova PLC has a one year low of $42.75 and a one year high of $64.47. The company has a 50 day simple moving average of $52.13 and a 200 day simple moving average of $52.45.

Analysts Set New Price Targets

A number of research analysts recently commented on LIVN shares. Robert W. Baird upped their target price on LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research note on Thursday, October 31st. The Goldman Sachs Group started coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a "buy" rating and a $65.00 price objective for the company. Mizuho decreased their target price on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a research report on Thursday, October 31st. StockNews.com lowered shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Saturday, November 16th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $75.00 price objective on shares of LivaNova in a report on Monday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $69.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.